T1	Encounter 25 36	outpatients
E1	Encounter:T1 
T2	Eq-Comparison 37 49	2 to 6 years
E2	Eq-Comparison:T2 Value:T41 Operator:T42 Value:T43 Temporal-Unit:T44
T3	Age 53 56	age
E3	Age:T3 
T4	Or 69 72	and
E4	Or:T4 
T5	And 81 84	who
E5	And:T5 
T6	Condition 89 107	physically healthy
E6	Condition:T6 Name:T47
T7	Condition 127 151	autism spectrum disorder
E7	Condition:T7 Name:T48
T8	And 201 204	and
E8	And:T8 
T9	Assertion 333 338	could
E9	Assertion:T9 
A1	Assertion-Type-Value E9 hypothetical
T10	Assertion 380 385	could
E10	Assertion:T10 
A2	Assertion-Type-Value E10 hypothetical
T11	Assertion 468 478	ability of
E11	Assertion:T11 
A3	Assertion-Type-Value E11 hypothetical
T12	Assertion 479 489	subject to
E12	Assertion:T12 
A4	Assertion-Type-Value E12 hypothetical
T13	Modifier 490 510	swallow the compound
E13	Modifier:T13 
T14	Drug 536 547	medications
E14	Drug:T14 
T15	Eq-Comparison 552 568	at least 2 weeks
E15	Eq-Comparison:T15 Operator:T51 Value:T52 Temporal-Unit:T53
T16	Eq-Comparison 570 577	4 weeks
E16	Eq-Comparison:T16 Value:T54 Temporal-Unit:T55
T17	Eq-Comparison 589 593	took
E17	Eq-Comparison:T17 
T18	Drug 594 604	fluoxetine
E18	Drug:T18 Name:T56
T19	Negation 612 614	no
E19	Negation:T19 
T20	Eq-Comparison 615 622	planned
E20	Eq-Comparison:T20 Temporal-Period:T57
T21	Procedure 634 660	psychosocial interventions
E21	Procedure:T21 
T22	Temporal-Connection 661 667	during
E22	Temporal-Connection:T22 
A5	Temporal-Connection-Type-Value E22 during
T23	Modifier 672 682	open-label
E23	Modifier:T23 
T24	Study 683 688	trial
E24	Study:T24 
T25	Condition 734 747	schizophrenia
E25	Condition:T25 Name:T60
T26	Condition 749 773	schizoaffective disorder
E26	Condition:T26 Name:T61
T27	Or 775 777	or
E27	Or:T27 
T28	Condition 778 796	psychotic disorder
E28	Condition:T28 Name:T62
T29	Eq-Comparison 827 832	prior
E29	Eq-Comparison:T29 Temporal-Period:T63
T30	Drug 851 863	Esomeprazole
E30	Drug:T30 Name:T64
T31	Eq-Comparison 870 876	active
E31	Eq-Comparison:T31 Temporal-Period:T65
T32	Condition 877 893	medical problems
E32	Condition:T32 
T33	Condition 902 919	unstable seizures
E33	Condition:T33 Name:T66
T34	Or 921 923	or
E34	Or:T34 
T35	Condition 936 952	physical illness
E35	Condition:T35 Name:T68
T36	Modifier 968 973	liver
E36	Modifier:T36 
T37	Or 974 976	or
E37	Or:T37 
T38	Modifier 977 982	renal
E38	Modifier:T38 
T39	Condition 983 992	pathology
E39	Condition:T39 Name:T70
T40	Encounter-Type 25 36	outpatients
A6	Encounter-Type-Value T40 inpatient
T41	Eq-Value 37 38	2
T42	Eq-Operator 39 41	to
A7	Eq-Operator-Value T42 BETWEEN
T43	Eq-Value 42 43	6
T44	Eq-Temporal-Unit 44 49	years
A8	Eq-Temporal-Unit-Value T44 year
T45	Life-Stage-And-Gender 63 68	males
A9	Life-Stage-And-Gender-Type T45 male
T46	Life-Stage-And-Gender 73 80	females
A10	Life-Stage-And-Gender-Type T46 female
T47	Condition-Name 100 107	healthy
T48	Condition-Name 127 151	autism spectrum disorder
T49	Condition-Name 490 510	swallow the compound
T50	Stability 517 523	stable
A11	Stability-Value T50 stable
T51	Eq-Operator 552 560	at least
A12	Eq-Operator-Value T51 GTEQ
T52	Eq-Value 561 562	2
T53	Eq-Temporal-Unit 563 568	weeks
A13	Eq-Temporal-Unit-Value T53 week
T54	Eq-Value 570 571	4
T55	Eq-Temporal-Unit 572 577	weeks
A14	Eq-Temporal-Unit-Value T55 week
T56	Drug-Name 594 604	fluoxetine
T57	Eq-Temporal-Period 615 622	planned
A15	Eq-Temporal-Period-Value T57 future
T58	Stability 623 630	changes
A16	Stability-Value T58 change
T59	Condition-Name 715 720	DSM-5
T60	Condition-Name 734 747	schizophrenia
T61	Condition-Name 749 773	schizoaffective disorder
T62	Condition-Name 778 796	psychotic disorder
T63	Eq-Temporal-Period 827 832	prior
A17	Eq-Temporal-Period-Value T63 past
T64	Drug-Name 851 863	Esomeprazole
T65	Eq-Temporal-Period 870 876	active
A18	Eq-Temporal-Period-Value T65 present
T66	Condition-Name 902 919	unstable seizures
T67	Severity 924 935	significant
A19	Severity-Value T67 severe
T68	Condition-Name 936 952	physical illness
T69	Severity 960 967	serious
A20	Severity-Value T69 severe
T70	Condition-Name 983 992	pathology
